American Journal of Medical Genetics Part A · 2015 · 13 citations · 16 references
Life SciencesGeneticsMolecular GeneticsHuman GeneticsMedical GeneticsMolecular PathologyClinical GenomicsGenetic DisordersGenetic SyndromesRare Disease GeneticsRas Family OncogenesAberrant Ras ActivationMapk Pathway MutationsPreclinical Drug DevelopmentPreclinical Drug TestingRas Pathway ActivationRas Signaling PathwayRas-mitogen-activated Protein Kinase SignalingRas-targeted Therapies
"The Third International Meeting on Genetic Disorders in the RAS/MAPK Pathway: Towards a Therapeutic Approach" was held at the Renaissance Orlando at SeaWorld Hotel (August 2-4, 2013). Seventy-one physicians and scientists attended the meeting, and parallel meetings were held by patient advocacy groups (CFC International, Costello Syndrome Family Network, NF Network and Noonan Syndrome Foundation). Parent and patient advocates opened the meeting with a panel discussion to set the stage regarding their hopes and expectations for therapeutic advances. In keeping with the theme on therapeutic development, the sessions followed a progression from description of the phenotype and definition of therapeutic endpoints, to definition of genomic changes, to identification of therapeutic targets in the RAS/MAPK pathway, to preclinical drug development and testing, to clinical trials. These proceedings will review the major points of discussion.
16
Germline mutations in HRAS proto-oncogene cause Costello syndrome
Yoko Aoki, Tetsuya Niihori, Hiroshi Kawame et al. · Nature Genetics · 2005 · 674 citations
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome
Tetsuya Niihori, Yoko Aoki, Yoko Narumi et al. · Nature Genetics · 2006 · 599 citations